Fecula Biotechnology has a strong research and development team that shone brightly at the medical exhibition.

Fecula Biotechnology obtained angel investment from the National Development Fund in 2020. In its four years since establishment, the company has taken advantage of its listing on the Emerging Stock Market to complete an initial internal audit and control system. This year, Fecula Biotechnology was awarded the 20th "National Innovation Award - Startup Company Award." Additionally, it was selected by the Agricultural Research Institute as a co-exhibitor at this year's medical exhibition under the theme "Transforming Agricultural Resources into Capital for Sustainable Health," showcasing its strong research and development capabilities with remarkable results.

Fecula Biotechnology boasts a robust team of four PhDs and three master's degree holders, demonstrating significant R&D strength in the development of new drugs and health products. The company has filed five invention patents for global deployment, secured seven domestic and international trademarks, and is preparing to submit two new drug research results to international scientific journals. With sponsorship from the Biotechnology Strategy Council and the Council of Agriculture, it launched its new drug "Oral Cancer Vaccine Platform" and health product "Probiotic Combined with Biotech Agricultural Extracts" at this year's medical exhibition, receiving enthusiastic responses from attendees and creating potential collaboration opportunities for health food sales and new drug development.

CEO Miles Chen stated that the company's core technology is its proprietary encapsulation technology for resistant starch, which can be applied in both new drug and health food development. By optimizing this technology through consumer experiences with encapsulated probiotic health foods, the effectiveness of oral new drugs can be enhanced. The development and sale of health foods also aim to achieve agricultural sustainability and revenue generation, expanding opportunities for new drug development and licensing.

Currently, Fecula has completed the extraction of active ingredients from four agricultural products, developed seven health products, and established distribution channels in the United States, Vietnam, Malaysia, and Taiwan. The oral new drugs have also completed the development of "fecal microbiota transplantation oral formulations" and the "oral cancer vaccine platform," along with obtaining animal efficacy validation. Fecula Biotechnology's R&D efforts have received repeated recognition. The young team aims to leverage Taiwan's agricultural resources through scientific and biotechnological validation to find higher added value, accelerating corporate social responsibility in sustainable agriculture and the circular economy. Furthermore, through the development of vaccine new drugs and subsequent international licensing, the company seeks to promote and showcase Taiwan's substantial R&D capabilities to the world. The strong ambition and research capabilities are key reasons for the company's repeated recognition with prestigious awards.

More Media Coverage>>https://www.chinatimes.com/newspapers/20231214000434-260204?chdtv